The president of the Abigail Alliance — the group that was the petitioner in that recent DC Circuit case on access to lifesaving drugs that have not yet received full-blown FDA approval — has a letter to the editor in today’s Washington Post. The last graph says:
We are confident that access to these drugs is possible while maintaining the Food and Drug Administration’s role in furthering medical research and protecting Americans from harmful products. Even as we proceed in court, we will work with the FDA and Congress to make that possible.
